請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33920
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭安理(Ann-Lii Cheng) | |
dc.contributor.author | Chia-Chi Lin | en |
dc.contributor.author | 林家齊 | zh_TW |
dc.date.accessioned | 2021-06-13T05:49:03Z | - |
dc.date.available | 2006-08-11 | |
dc.date.copyright | 2006-08-11 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-10 | |
dc.identifier.citation | Anonymous (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 354: 533-540
Anonymous (1995) Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration. Br J Urol 75: 206-213 Anonymous (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361: 1927-1934 Anonymous (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48: 202-205 Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G (2005) Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 92: 645-650 Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17: 3173-3181 Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, Herr H, Scher HI, Icasiano E, Higgins G (2000) Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88: 1671-1678 Bajorin D (2004) The phase III candidate: can we improve the science of selection? J Clin Oncol 22: 211-213 Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA (2004) Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22: 220-228 Bamias A, Tiliakos I, Karali MD, Dimopoulos MA (2006) Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol 17: 553-561 Bazarbashi S, Pai C, Raja MA, Rahal M, Ezzat A, Hanash K (2003) Phase II trial of cisplatin, 5-fluorouracil, and interferon-alpha-2B as first line treatment of advanced urothelial cancer. Urol Oncol 21: 185-189 Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, az-Rubio E, Cortes-Funes H, Baselga J (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95: 751-757 Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, Saenz A, Lopez-Brea M, Font A, Nogue M, Bastus R, Climent MA, de la Cruz JJ, Albanell J, Banus JM, Gallardo E, az-Rubio E, Cortes-Funes H, Baselga J (2000) Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18: 3247-3255 Burch PA, Richardson RL, Cha SS, Sargent DJ, Pitot HC, Kaur JS, Camoriano JK (2000) Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 164: 1538-1542 Caffo O, Fellin G, Graffer U, Luciani L (1996) Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer 78: 1089-1097 Castagneto B, Zai S, Marenco D, Bertetto O, Repetto L, Scaltriti L, Mencoboni M, Ferraris V, Botta M (2004) Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology 67: 27-32 Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W (2005) Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62: 309-317 Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ (2004) Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22: 1007-1013 Chen CH, George SL (1985) The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med 4: 39-46 Cheng AL, Yeh KH, Lin JT, Hsu C, Liu MY (1998) Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer. Anticancer Res 18: 1267-1272 Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH, Chen KY (1995) Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.[see comment]. Cancer 76: 2186-2192 Cox D (1972) Regression models and life tables. J R Stat Soc 34: 187-220 Culine S, Theodore C, De SM, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B, James N (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94: 1395-1401 Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V (2001) Cystectomy for bladder cancer: a contemporary series. J Urol 165: 1111-1116 de Wit R. (2003) Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97: 2120-2126 Di Lorenzo G, Autorino R, Giordano A, Giuliano M, D'Armiento M, Bianco AR, De PS (2004) FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J Clin Oncol 34: 747-750 Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, Karayannis A, Varkarakis I, Aravantinos G, Zervas A, Pantazopoulos D, Fountzilas G, Bamias A, Kyriakakis Z, Anagnostopoulos A, Giannopoulos A, Kosmidis P (1999) Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 10: 1385-1388 Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, Icasiano E, Boyle MG, Bajorin DF (2000) Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 18: 840-846 Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G (2000) Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 18: 1058-1061 Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G (2004) Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100: 1639-1645 Dunst J, Sauer R, Schrott KM, Kuhn R, Wittekind C, Altendorf-Hofmann A (1994) Organ-sparing treatment of advanced bladder cancer: a 10-year experience. International Journal of Radiation Oncology, Biology, Physics 30: 261-266 Fechner G, Siener R, Reimann M, Kobalz L, Albers P (2006) Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 60: 27-31 Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, . (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422 Garcia del Muro X, Condom E, Vigues F, Castellsague X, Figueras A, Munoz J, Sola J, Soler T, Capella G, Germa JR (2004) p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100: 1859-1867 Garcia del Muro X, Marcuello E, Guma J, Paz-Ares L, Climent MA, Carles J, Parra MS, Tisaire JL, Maroto P, Germa JR (2002) Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 86: 326-330 Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, Sanchez JD, Shapiro RM, Figlin RA (2003) A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98: 1863-1869 Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, Vere White RW, Sarosdy MF, Wood DP, Jr., Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349: 859-866 Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU (2003) RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57: 665-672 Hainsworth JD, Meluch AA, Litchy S, Schnell FM, Bearden JD, Yost K, Greco FA (2005) Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103: 2298-2303 Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G (2002) Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 62: 215-225 Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530-534 Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, Colardelle F, Brunel P, Baillet F (1993) Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 11: 2150-2157 Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS (2001) Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res 21: 711-715 Hussain M, Petrylak D, Dunn R, Vaishampayan U, Lara PN, Chatta G, Nanus D, Glode LM, Trump D, Chen H, Smith DC (2005) Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Oncol (Meeting Abstracts) 23: 4507 Hussain M, Vaishampayan U, Du W, Redman B, Smith DC (2001) Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19: 2527-2533 Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, Spooner D, James ND (2004) A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 91: 844-849 Jeffery GM, Mead GM (1992) CMV chemotherapy for advanced transitional cell carcinoma. Br J Cancer 66: 542-546 Jimenez RE, Hussain M, Bianco FJ, Jr., Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP, Jr., Grignon DJ (2001) Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7: 2440-2447 Johnston PG, Geoffrey F, Drake J, Voeller D, Grem JL, Allegra CJ (1996) The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 32A: 2148-2154 Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi K (1996) Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704-710 Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481 Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W (2000a) Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921-1927 Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM (2004) A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22: 393-397 Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, Zlotecki RA, Sause WT, True LD (2000b) The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5: 471-476 Kish JA, Wolf MK, Schellhammer PF, Hussain MH, Einstein AB, Crawford ED (1997) Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. Am J Clin Oncol 20: 327-330 Klaassen U, Wilke H, Weyhofen R, Harstrick A, Eberhardt W, Muller C, Korn M, Hanske M, Diergarten K, Seeber S (1998) Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anticancer Drugs 9: 203-207 Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C (2000) A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83: 458-462 Kosmidis PA, Bacoyiannis C, Fountzilas G, Aravantinos G, Tsavaris N, Milathianakis C, Skarlos D (1997) 5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group. Ann Oncol 8: 373-378 Krege S, Rembrink V, Borgermann C, Otto T, Rubben H (2001) Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol 165: 67-71 Lara PN, Jr., Meyers FJ, Law LY, Dawson NA, Houston J, Lauder I, Edelman MJ (2004) Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer 100: 82-88 Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, Einhorn LH, Sweeney CJ (2005) Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 23: 1185-1191 Lin CC, Hsu CH, Chen J, Tsai TC, Cheng AL, Pu YS (2001) A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res 21: 1385-1390 Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, Pu YS (2006) Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma -- an effective regimen with low toxicity. Cancer 106: 1269-1275 Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS (2007) Phase II trial of weekly paclitaxel, cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (TP-HDFL) for metastatic urothelial carcinoma. J Urol 177: (in press) Lindley CM, Gordon TR, Tremont SJ (1991) Cisplatin-based chemotherapy in a renal transplant recipient. Cancer 68: 1113-1117 Loehrer PJ, Sr., Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, . (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10: 1066-1073 Loehrer PJ, Sr., Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH (1994) Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 12: 483-488 Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050-1055 Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ (1995) Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13: 2272-2277 Lorusso V, Crucitta E, Silvestris N, Rosati G, Manzione L, De LM, Palmeri S, Gebbia V, Mancarella S, Sobrero A, Pezzella G, Comella P, Mangiameli A, Muci D (2005) Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium. Oncol Rep 13: 283-287 Lorusso V, Manzione L, De VF, Antimi M, Selvaggi FP, De LM (2000) Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164: 53-56 Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M, De LM (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34: 1208-1212 Machiels JP, Wulfing C, Richel DJ, Beuzeboc P, Garcia Del Muro X, Grimm MO, Farrell J, Colman JR, El-Hariry IA (2004) A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis. J Clin Oncol (Meeting Abstracts) 22: 4615 Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354: 93-99 Maluf F, Hilton S, Nanus D, Herr H, Mazumdar M, Higgins G, Novick S, Boyle MG, Thomas F, Bajorin DF (2000) Sequential doxorubicin/gemcitabine (AG) and ifosfamide, paclitaxel, and cisplatin (ITP) chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium (TCC). Proc Am Soc Clin Oncol 19: (abstr 1344) Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170 McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15: 1853-1857 Mead GM, Russell M, Clark P, Harland SJ, Harper PG, Cowan R, Roberts JT, Uscinska BM, Griffiths GO, Parmar MK (1998) A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 78: 1067-1075 Meluch AA, Greco FA, Burris HA, III, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 19: 3018-3024 Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214 Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19: 4005-4013 Mokarim A, Uetani M, Hayashi N, Sakamoto I, Minami K, Ogawa Y, Ochi M, Matsuoka Y, Hayashi K, Nomata K (1997) Combined intraarterial chemotherapy and radiotherapy in the treatment of bladder carcinoma. Cancer 80: 1776-1785 Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445 Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 2876-2881 Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619-1625 Nishiyama M, Yamamoto W, Park JS, Okamoto R, Hanaoka H, Takano H, Saito N, Matsukawa M, Shirasaka T, Kurihara M (1999) Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 5: 2620-2628 Oh WK, Manola J, Richie JP, Loughlin KR, Kantoff PW (1999) A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. Cancer 86: 1329-1334 Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W, Garbeglio A (1991) Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 145: 45-50 Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ (2002) Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20: 2965-2970 Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J (1997) Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 75: 606-607 Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H (2003) Review of a promising new agent--pemetrexed disodium. Cancer 97: 2056-2063 Pectasides D, Aravantinos G, Kalofonos H, Kiamouris C, Bafaloukos D, Xiros N, Nicolaides C, Visvikis A, Dimopoulos MA (2001) Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 12: 1417-1422 Pectasides D, Glotsos J, Bountouroglou N, Kouloubinis A, Mitakidis N, Karvounis N, Ziras N, Athanassiou A (2002) Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 13: 243-250 Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19: 4216-4223 Philips G, Halabi S, Sanford B, Bajorin D, Small E (2004) Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102. J Clin Oncol (Meeting Abstracts) 22: 4540 Pollera CF, Ceribelli A, Crecco M, Calabresi F (1994) Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182-184 Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1418 Pu YS, Chen J, Huang CY, Guan JY, Lu SH, Hour TC (2001) Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells. J Urol 166: 2082-2085 Redman BG, Smith DC, Flaherty L, Du W, Hussain M (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16: 1844-1848 Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA (2003) Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 88: 1191-1198 Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R (2002a) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20: 3061-3071 Rodel C, Grabenbauer GG, Kuhn R, Zorcher T, Papadopoulos T, Dunst J, Schrott KM, Sauer R (2002b) Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys 52: 1303-1309 Rosenberg JE, Carroll PR, Small EJ (2005) Update on chemotherapy for advanced bladder cancer. J Urol 174: 14-20 Roth BJ, Bajorin DF (1995) Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153: 894-900 Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270 Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692-1703 Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P (1998) Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 40: 121-127 Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Sr., Trump D (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15: 2564-2569 Scanlon KJ, Newman EM, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 83: 8923-8925 Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y, . (1993) Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11: 408-414 Sengelov L, Kamby C, Lund B, Engelholm SA (1998) Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 16: 3392-3397 Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP (2004) p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22: 1014-1024 Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, Althausen AF, Zietman AL (2002) Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60: 62-67 Shipley WU, Prout GR, Jr., Kaufman SD, Perrone TL (1987) Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation. Cancer 60: 514-520 Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16: 3576-3583 Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Jr., Smith TL, Williams D, Logothetis CJ (2002) Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20: 1361-1367 Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, Crawford ED (2000) Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 18: 2537-2544 Srinivas S, Guardino AE (2005) A nonplatinum combination in metastatic transitional cell carcinoma. Am J Clin Oncol 28: 114-118 Stadler WM, Hayden A, von der MH, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M (2002) Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7: 153-157 Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394-3398 Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19: 666-675 Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A (2001a) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92: 2993-2998 Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de BC, Collette L (2001b) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19: 2638-2646 Sternberg CN, de MP, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de BC, Collette L (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42: 50-54 Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Jr., Bander N, Weiselberg LR, . (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461-469 Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14: 197-207<BR | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33920 | - |
dc.description.abstract | 膀胱癌最常見的細胞型態為泌尿上皮細胞癌(urothelial carcinoma)(>90%)。膀胱癌根據原發腫瘤侵犯的深度可分為:T1為腫瘤侵犯至lamina propria、T2為腫瘤侵犯至膀胱肌肉層、T3為腫瘤侵犯至膀胱周圍脂肪、T4為腫瘤侵犯至膀胱周圍器官。其中T1稱為表淺性膀胱癌(superficial bladder cancer),其標準治療為經尿道腫瘤切除術,復發後若仍為表淺性,可考慮膀胱灌注藥物(如BCG、doxorubicin、mitomycin-C)以減少復發的機會;T2稱為肌肉層侵犯膀胱癌(muscle-invasive bladder cancer),其標準治療,在美國多為根除性膀胱切除手術(radical cystectomy),在歐洲多為全膀胱放射治療(whole bladder irradiation),至於手術前後化學治療的角色仍待進一步的評估;M1稱為遠端轉移膀胱癌(metastatic bladder cancer),其標準治療為全身性化學治療,在美國多使用MVAC處方,在歐洲多使用CMV處方。
台灣泌尿上皮細胞癌的特點在於上泌尿道(即腎盂及輸尿管)相對於膀胱的比例較高,手術切除腫瘤常包括腎臟切除,導致腎功能不佳。 在本論文中,我們試圖將5-fluorouracil(5-FU),一個在泌尿上皮細胞癌過去並不常使用的藥物,與cisplatin為基礎的化學治療做結合。將分成三個部份來討論:第一,我們發展新的以cisplatin及5-FU為基礎的第一線處方;第二,我們進一部探討這些新處方,包括分析可以預測反應率或存活期的臨床特徵、測試這些新處方在特殊晚期病患(例如;病患接受腎臟移植又合併有轉移性移形上皮細胞癌)的可行性、測試這些新處方在特殊非晚期病患(例如;肌肉層侵犯膀胱一型上皮細胞癌的病患想保留膀胱)的可行性;第三,我們發展第二線處方來治療對cisplatin及5-FU為基礎的治療失敗的轉移性移形上皮細胞癌。 | zh_TW |
dc.description.abstract | Urothelial carcinoma (UC) is the second most common genitourinary malignancy. In 2002, the crude incidence in Taiwan is 7 cases/100,000/year and the mortality 2 cases/100 000/year. Most cases present with superficial disease. Nevertheless, 20% have muscle-invasive disease at presentation, while 5% present with metastatic disease. In addition, 50% of patients undergoing radical surgery for muscle-invasive UC will relapse. Relapses cannot be cured by local treatment in the majority of cases. Therefore, surgically inoperable disease comprises three distinct groups: inoperable disease due to local extension or grossly involved pelvic or paraortic lymph node (stages T4b, N2-3), metastatic disease at diagnosis, or recurrent disease after radical surgery. Systemic chemotherapy represents the most useful option for patients with surgically incurable disease.
The landmark of systemic chemotherapy in advanced UC was the development of the combination of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 1983. Its activity against UC has been considerable with response rates (RR) of >50%, 3-year survival of 20-25% and median survival of >1 year [Sternberg et al., 1988]. Furthermore, MVAC was shown to be superior to single-agent cisplatin in a randomized trial establishing the role of combination chemotherapy in advanced UC [Loehrer, Sr. et al., 1992]. Several MVAC-like regimes have also been studied. The combination of cisplatin, methotrexate and vinblastine (CMV) was contemporary with MVAC and was developed at Stanford University. In a randomized study of 214 patients it was shown to be superior to the combination of methotrexate and vinblastine [Mead et al., 1998], underlying the importance of cisplatin in prolonging survival and establishing the routine use of cisplatin-based combination chemotherapy. The omission of vinblastine from MVAC led to the MD Anderson Cancer Center (MDACC) CISCA regimen (cisplatin, cyclophosphamide and doxorubicin). The CISCA regimen was found to be inferior to MVAC in a randomized trial of 110 patients [Logothetis et al., 1990]. Therefore, most centers worldwide have considered MVAC regimen as the standard treatment for advanced UC cancer for almost two decades. Despite superior outcomes severe toxicity significantly limits MVAC usefulness for advanced UC. Ten to 20% grade 3 and 4 mucositis, 20 to 30% grade 3 and 4 leukopenia, and a 3 to 4% toxic death rate are consistently seen in randomized trials. Perhaps most importantly only a small subset of patients treated with MVAC has long-term disease-free survival (3.7% at 6 years) [Saxman et al., 1997]. Two strategies have therefore been used to improve over MVAC: the use of granulocyte-colony stimulating factor (G-CSF) and the study of new combinations. The use of G-CSF can reduce myelotoxicity but also allowed for the administration of MVAC in a more dose-dense fashion [Gabrilove et al., 1988; Loehrer, Sr. et al., 1994; Seidman et al., 1993; Logothetis et al., 1995]. The results of phase II studies indicated that the efficacy of MVAC might be improved by dose intensification. In order to change the toxicity profile and possibly increase the efficacy of MVAC, other combinations based on platinum have been studied. The development of novel platinum-based combinations has focused on taxanes and gemcitabine, mainly because of their single-agent activity and their synergic effects with platinum. The gemcitabine-cisplatin combination (GC) has been evaluated in three studies that involved a total of 121 patients and used different administration schedules. All studies showed high overall RR and complete response (CR) rate, while median overall survival (OS) was also encouraging at 12-14 months [von der Maase et al., 1999; Kaufman et al., 2000a; Moore et al., 1999]. With longer follow-up, the median OS was 13.2 months and estimated 4-year survival was 13% [Stadler et al., 2002]. The combination of docetaxel and cisplatin every 3 weeks has also been evaluated in three studies. In a total of 123 patients, the overall RR ranged from 52% to 62% and the median OS was reported to be 8-14 months [Dimopoulos et al., 1999; Sengelov et al., 1998; Garcia del Muro et al., 2002]. Regimens of combined paclitaxel and carboplatin, usually given every 3 weeks, were evaluated in three studies, involving a total of 77 patients. The overall RR ranged from 21% to 65% with the median OS around 9 months [Small et al., 2000; Redman et al., 1998; Zielinski et al., 1998]. The promising efficacy and the favorable toxicity profile shown in the above-mentioned studies led to four more recent randomized studies comparing MVAC with other combinations of platinum. An EORTC study showed that intensified MVAC (HD MVAC) with G-CSF support was less toxic than classic MVAC. The RR, CR rate and progression-free survival (PFS) were superior for HD MVAC but the difference in OS was non-significant in the initial publication [Sternberg et al., 2001b]. With longer follow-up, the initial results have been confirmed with PFS and morality hazard ratios of 0.73 and 0.76, respectively and 2-year and 5-year survival rates of 36% compared with 26% and 21% compared with 13% for HD MVAC and classic MVAC, respectively [Sternberg et al., 2006]. In another randomized study the combination of GC was found to be equally effective with regard to response time to progression and survival but less toxic than classic MVAC [von der Maase et al., 2000]. This trial was powered to detect a 33% (4 months) difference in survival between the arms; it was not designed to prove that the treatments were equivalent, which would have required a much larger trial. Long-term results of this study have also been published recently, confirming similar 5-year survival and PFS rates for GC (13% and 9.8%) and MVAC (15.3% and 11.3%) [von der Maase et al., 2005b]. In the third randomized study the combination docetaxel–cisplatin was compared with G-CSF supported MVAC. Docetaxel–cisplatin was found to be inferior to MVAC, although the difference in survival did not reach statistical significance due to an imbalance in performance status between the two arms [Bamias et al., 2004]. The phase III study designed to compare MVAC with paclitaxel-carboplatin never completed accrual and, therefore, no conclusions can be drawn [Dreicer et al., 2004]. The results of the former two studies indicate that the standard in chemotherapy for advanced UC may be changing. As shown above the last decade has been characterized by the use of chemotherapy doublets, some of which were compared with standard MVAC. Nevertheless, the development of several active agents, as well as the wider application of G-CSF, led to the study of three or more drug combinations in advanced UC. The first approach is to add a new agent, either a taxane or gemcitabine, to the ifosfamide-cisplatin regimen. The first triplet was developed at the MSKCC, who tested the combination of ifosfamide, paclitaxel, and cisplatin (ITP). They reported a 68% RR and an impressive median survival of 18 months [Bajorin et al., 2000]. Based on these results and the Norton-Simon hypothesis of chemotherapy sensitivity (Non-cross resistant sequenced chemotherapy has been shown to improve outcomes in breast cancer.), the same group sequentially administered five agents to facilitate drug delivery [Dodd et al., 2000]: six cycles of doxorubicin and gemcitabine (AG) were followed by four cycles of ITP. Fifty-six patients have been treated at the MSKCC with an overall RR of 73%, which is higher than expected with either AG or ITP [Maluf et al., 2000]. The second triplet was developed at the MDACC, who tested the combination of ifosfamide, gemcitabine, and cisplatin. They reported a 41% RR [Pagliaro et al., 2002]. The second approach is to add a platinum, to the taxane-gemcitabine regimen. Bellmunt et al. [Bellmunt et al., 2000] and the Spanish Oncology Genitourinary Group have conducted a phase I/II trial of the combination of gemcitabine, cisplatin, and paclitaxel (GCP). The overall RR and CR rates at the phase II part of the study were 76% and 26%, respectively, and the median survival was 15.6 months. In a randomized phase II study, Lorusso et al. [Lorusso et al., 2005] reported an RR of 43% with a CR rate of 12% among 42 patients treated with GCP. Response rates were similar to those of GC. Nevertheless, this study was underpowered to detect significant differences in survival. Pectasides et al. [Pectasides et al., 2002] studied a weekly regimen of gemcitabine, cisplatin, and docetaxel in 35 patients. A RR of 65% and a median survival of 15.5 months were reported in a population of predominantly good prognosis (77% PS 0 or 1). Hussain et al. [Hussain et al., 2001] conducted a phase II trial evaluating the efficacy of the combination gemctabine-carboplatin-paclitaxel in patients with advanced UC. Most of the 49 patients who were enrolled would have been eligible for cisplatin-based chemotherapy. The overall RR was 68%, with a CR rate of 32% and a median survival of 14.7 months. In a similarly designed study, Hainsworth et al. [Hainsworth et al., 2005] failed to duplicate these results. Lower RR (43%), CR rate (12%) and median survival (11 months) in 60 patients with similar prognostic features were reported. The third approach is to add a non-platinum, to the taxane-gemcitabine regimen. The preliminary results of a phase I/II study by Lara et al. [Lara, Jr. et al., 2004] reported the use of a non-cisplatin triplet built up with paclitaxel, methotrexate and gemcitabine. In 21 evaluable patients the overall RR was 57% (6 CRs and 3 PRs), median overall and progression-free survival was 18 and 6.3 months, respectively and the most common toxicity was neutropenia. Data from triplet studies so far demonstrate the feasibility of such combinations, since treatment was generally well tolerated. The precise role of these combinations will be clarified by the EORTC randomized trial (30987), which compared GCP with GC and has recently completed accrual [de Wit R., 2003]. In this thesis, we incorporated 5-fluorouracil (5-FU), a chemotherapeutic agent uncommonly used in advanced UC, to cisplatin-based chemotherapy. Three aspects will be addressed: In the first part, we developed two new first-line regimens based on cisplatin and 5-FU. In the second part, we defined the effect of pretreatment patient characteristics on clinical outcome, tested the feasibility of these new regimens in the setting of renal allograft recipients with metastatic UC, and incorporated these new regimens to a bladder-conserving strategy in patients with muscle-invasive bladder UC. In the third part, we developed second-line regimens for UC after failure to these new cisplatin and 5-FU-based regimens. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T05:49:03Z (GMT). No. of bitstreams: 1 ntu-95-D89421002-1.pdf: 1657140 bytes, checksum: 973e5d82522fce04cffd581ec32c3c64 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 封 面
口試委員、指導教授與所長簽名表 國家圖書館碩博士授權書 致 謝 目 錄 中文摘要(Abstract in Chinese) 1 緒 論(Introduction) 2 研究方法與材料(Materials and Methods) 23 結 果(Results) 29 討 論(Discussion) 35 展 望(Perspectives) 51 論文英文簡述(Abstract in English) 60 參考文獻(References) 76 圖 表(Tables and Figures) 94 附 錄(Appendix) 125 | |
dc.language.iso | zh-TW | |
dc.title | 泌尿上皮細胞癌全身性化學治療之研究 | zh_TW |
dc.title | Study of Systemic Chemotherapy in Urothelial Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 郭明良(Min-Liang Kuo) | |
dc.contributor.oralexamcommittee | 賴明陽(Ming-Yang Lai),張俊彥(Jang-Yang Chang),陳立宗(Li-Tzong Chen),蒲永孝(Yeong-Shiau Pu) | |
dc.subject.keyword | 膀胱癌,移形上皮細胞癌,抗癌合併化學治療處方,太平洋紫杉醇, | zh_TW |
dc.subject.keyword | bladder neoplasms,carcinoma, transitional cell,antineoplastic combined chemotherapy protocols,fluorouracil,paclitaxel, | en |
dc.relation.page | 126 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-10 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 1.62 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。